McKesson Corporation (NYSE:MCK) has emerged as one of the best performing S&P 500 stocks in the last five years, according to a recent report. On February 5, 2026, BofA reaffirmed its ‘Buy’ rating on McKesson Corporation and raised its price target from $950 to $970. The firm highlighted the company’s strong third-quarter performance, with revenue and EPS surpassing street expectations.
The North American Pharmaceutical segment showed solid performance, while the Oncology & Multispecialty segment continued to demonstrate strength. As a result, BofA increased its FY26 and FY27 EPS projections for McKesson Corporation. This positive analyst update followed the company’s Q3 earnings and outlook update on February 4, 2026, where McKesson raised its fiscal 2026 adjusted EPS forecast.
In addition to exceeding revenue and EPS forecasts, McKesson Corporation reported third-quarter revenue of $106.16 billion and adjusted EPS of $9.34. The U.S. pharmaceutical segment saw a 9% increase in sales to $88.30 billion, driven by strong demand for specialty drugs and prescription volumes.
As a healthcare services company, McKesson Corporation offers pharmaceutical distribution, specialty drug solutions, prescription technology services, and medical-surgical supplies in the United States and international markets. While the company presents investment potential, some AI stocks may offer greater upside potential and lower downside risk.
For investors seeking undervalued AI stocks that could benefit from Trump-era tariffs and the onshoring trend, a free report on the best short-term AI stock is available. To stay informed about the latest investment opportunities, consider exploring the best stocks to buy right now and 10 stocks under $1 that are poised for explosive growth.
Disclosure: None.
This rewritten content integrates seamlessly into a WordPress platform, providing readers with valuable insights into McKesson Corporation’s performance and potential investment opportunities.
